Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ahmed M Musa

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
The Journal of Infectious Diseases|August 21, 2024
Disease-Specific Differences in Pharmacokinetics of Paromomycin and Miltefosine Between Post-Kala-Azar Dermal Leishmaniasis and Visceral Leishmaniasis Patients in Eastern AfricaWan-Yu Chu, Luka Verrest, Brima M Younis, et al.
The Journal of Antimicrobial Chemotherapy|September 30, 2017
Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic studyThomas P C Dorlo, Anke E Kip, Brima M Younis, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 13, 2021
Blood Parasite Load as an Early Marker to Predict Treatment Response in Visceral Leishmaniasis in Eastern AfricaLuka Verrest, Anke E Kip, Ahmed M Musa, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 30, 2021
Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in SudanBrima M Younis, Mohamed Osman, Eltahir A G Khalil, et al.
The Journal of Infectious Diseases|July 12, 2011
Genetic and functional evidence implicating DLL1 as the gene that influences susceptibility to visceral leishmaniasis at chromosome 6q27Michaela Fakiola, E Nancy Miller, Manal Fadl, et al.
Plos Neglected Tropical Diseases|January 24, 2014
Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trialEltahir A G Khalil, Teklu Weldegebreal, Brima M Younis, et al.
Clinical Drug Investigation|January 10, 2017
Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance ProgrammeRobert Kimutai, Ahmed M Musa, Simon Njoroge, et al.
Clinical Pharmacokinetics|June 9, 2021
Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis PatientsLuka Verrest, Monique Wasunna, Gilbert Kokwaro, et al.
Molecular Therapy. Methods & Clinical Development|September 10, 2024
A randomized, double-blind phase 2b trial to evaluate efficacy of ChAd63-KH for treatment of post kala-azar dermal leishmaniasisBrima M Younis, Rebecca Wiggins, Eltahir A G Khalil, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 27, 2022
Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry TrialAhmed M Musa, Jane Mbui, Rezika Mohammed, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
The Journal of Infectious Diseases|August 21, 2024
Disease-Specific Differences in Pharmacokinetics of Paromomycin and Miltefosine Between Post-Kala-Azar Dermal Leishmaniasis and Visceral Leishmaniasis Patients in Eastern AfricaWan-Yu Chu, Luka Verrest, Brima M Younis, et al.
The Journal of Antimicrobial Chemotherapy|September 30, 2017
Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic studyThomas P C Dorlo, Anke E Kip, Brima M Younis, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 13, 2021
Blood Parasite Load as an Early Marker to Predict Treatment Response in Visceral Leishmaniasis in Eastern AfricaLuka Verrest, Anke E Kip, Ahmed M Musa, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 30, 2021
Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in SudanBrima M Younis, Mohamed Osman, Eltahir A G Khalil, et al.
The Journal of Infectious Diseases|July 12, 2011
Genetic and functional evidence implicating DLL1 as the gene that influences susceptibility to visceral leishmaniasis at chromosome 6q27Michaela Fakiola, E Nancy Miller, Manal Fadl, et al.
Plos Neglected Tropical Diseases|January 24, 2014
Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trialEltahir A G Khalil, Teklu Weldegebreal, Brima M Younis, et al.
Clinical Drug Investigation|January 10, 2017
Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance ProgrammeRobert Kimutai, Ahmed M Musa, Simon Njoroge, et al.
Clinical Pharmacokinetics|June 9, 2021
Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis PatientsLuka Verrest, Monique Wasunna, Gilbert Kokwaro, et al.
Molecular Therapy. Methods & Clinical Development|September 10, 2024
A randomized, double-blind phase 2b trial to evaluate efficacy of ChAd63-KH for treatment of post kala-azar dermal leishmaniasisBrima M Younis, Rebecca Wiggins, Eltahir A G Khalil, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 27, 2022
Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry TrialAhmed M Musa, Jane Mbui, Rezika Mohammed, et al.
Pageof 4